Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Barakat

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Managed Care & Specialty Pharmacy|March 28, 2025
Transforming retinal disease management through diabetes careCatherine M Lockhart, Mark R Barakat, Jeffrey D Dunn, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 11, 2025
Human Factors Studies to Assess the Usability of the Faricimab Prefilled SyringeMark R Barakat, Henry M Kwong, Gelson Marcon, et al.
Ophthalmology Science|September 27, 2024
Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation TrialMark R Barakat, David Brown, Allen Hu, et al.
Translational Vision Science & Technology|November 5, 2020
Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal DisordersChen-Rei Wan, Barry Kapik, Charles C Wykoff, et al.
The British Journal of Ophthalmology|February 6, 2021
Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)Christopher Ryan Henry, Milan Shah, Mark R Barakat, et al.
American Journal of Ophthalmology|November 6, 2021
Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular EdemaThomas A Ciulla, Barry Kapik, Mark R Barakat, et al.
The British Journal of Ophthalmology|March 13, 2021
Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)Rahul N Khurana, Pauline Merrill, Steven Yeh, et al.
JAMA Ophthalmology|November 24, 2021
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare MapArshad M Khanani, Marco A Zarbin, Mark R Barakat, et al.
Retina (Philadelphia, Pa.)|March 9, 2023
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World EvidenceCharles C Wykoff, Hidetaka Matsumoto, Mark R Barakat, et al.
Ophthalmology|March 8, 2003
Clinicopathologic effects of mutant GUCY2D in Leber congenital amaurosisAnn H Milam, Mark R Barakat, Nisha Gupta, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Managed Care & Specialty Pharmacy|March 28, 2025
Transforming retinal disease management through diabetes careCatherine M Lockhart, Mark R Barakat, Jeffrey D Dunn, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 11, 2025
Human Factors Studies to Assess the Usability of the Faricimab Prefilled SyringeMark R Barakat, Henry M Kwong, Gelson Marcon, et al.
Ophthalmology Science|September 27, 2024
Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation TrialMark R Barakat, David Brown, Allen Hu, et al.
Translational Vision Science & Technology|November 5, 2020
Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal DisordersChen-Rei Wan, Barry Kapik, Charles C Wykoff, et al.
The British Journal of Ophthalmology|February 6, 2021
Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)Christopher Ryan Henry, Milan Shah, Mark R Barakat, et al.
American Journal of Ophthalmology|November 6, 2021
Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular EdemaThomas A Ciulla, Barry Kapik, Mark R Barakat, et al.
The British Journal of Ophthalmology|March 13, 2021
Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)Rahul N Khurana, Pauline Merrill, Steven Yeh, et al.
JAMA Ophthalmology|November 24, 2021
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare MapArshad M Khanani, Marco A Zarbin, Mark R Barakat, et al.
Retina (Philadelphia, Pa.)|March 9, 2023
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World EvidenceCharles C Wykoff, Hidetaka Matsumoto, Mark R Barakat, et al.
Ophthalmology|March 8, 2003
Clinicopathologic effects of mutant GUCY2D in Leber congenital amaurosisAnn H Milam, Mark R Barakat, Nisha Gupta, et al.
Pageof 3